Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Antares Pharma, a developer and marketer of novel parenteral pharmaceuticals, has dosed its first rheumatoid arthritis patient in a VIBEX MTX clinical trial.
Subscribe to our email newsletter
The study will evaluate several dose strengths of VIBEX MTX which is being developed for the treatment of rheumatoid arthritis.
VIBEX MTX is Antares’ proprietary – wholly owned methotrexate injection system engineered for rapid self-administration by patients – and protected by several issued and pending patents.
Antares has already conducted in-vivo, pre-clinical studies which demonstrated reproducible pharmacokinetics and good injection site tolerance when methotrexate was delivered using the VIBEX technology.
Antares president and CEO Paul Wotton said that a significant number of patients are unable to tolerate methotrexate when given orally, but when it is administered in combination with injectable biological products, VIBEX MTX may represent a significant revenue opportunity for Antares; potentially as early as in 2013.